Skip to main content

Media & Press relations


Our latest press releases

October 26, 2023

Third-Quarter 2023 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023. Consolidated sales amounted to €2,668 million for the first nine months of 2023.

Swipe for more

  • October 19, 2023

    bioMérieux makes strategic investment in Oxford Nanopore

    Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics (“IVD”) today announce that bioMérieux is making an immediate £70M investment in Oxford Nanopore.
    Read more
  • October 13, 2023

    bioMérieux announces CE-marking of VIDAS® TBI (GFAP, UCH-L1)

    bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® TBI (GFAP, UCH-L1), a blood test to support assessment of patients with mild traumatic brain injury (mTBI), based on a unique combination of brain biomarkers: GFAP and UCH-L1*.
    Read more
  • October 11, 2023

    Launch of a new industrial chair, in Lyon on viral respiratory infections

    On October 11, 2023, the REVIDA Industrial Chair for Respiratory Infectious Diseases, led by researcher Sophie Trouillet-Assant (UCBL / HCL), was officially launched by Claude Bernard Lyon 1 University, Hospices Civils de Lyon, and bioMérieux, with the support of the Agence nationale de la recherche (National research agency, in France).
    Read more

Media contacts

Olivier Rescanière

Phone: (+33) (0)4 78 87 20 00 


Romain Duchez

Phone: (+33) (0)4 78 87 20 00 

Corporate Library